Neurotrophic factor delivery as a protective treatment for glaucoma |
| |
| Authors: | Thomas V. Johnson Natalie D. Bull Keith R. Martin |
| |
| Affiliation: | aCentre for Brain Repair, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK;bDepartment of Ophthalmology, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK;cMolecular Mechanisms of Glaucoma Section, Laboratory of Molecular and Developmental Biology, National Eye Institute, National Institutes of Health, Bethesda, MD, USA |
| |
| Abstract: | Glaucoma is a progressive optic neuropathy and a major cause of visual impairment worldwide. Neuroprotective therapies for glaucoma aim to ameliorate retinal ganglion cell degeneration through direct or indirect action on these neurons. Neurotrophic factor (NTF) delivery is a key target for the development of potential neuroprotective glaucoma treatments. This article will critically summarize the evidence that NTF deprivation and/or dysfunction plays a role in the pathogenesis of glaucoma. Experimental support for the neuroprotective potential of NTF supplementation in animal models of glaucoma will be reviewed, in particular for brain-derived neurotrophic factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Finally, the challenges of clinical translation will be considered with an emphasis on the most promising NTF delivery strategies including slow-release drug delivery, gene therapy, and cell transplantation. |
| |
| Keywords: | glaucoma neurotrophic factor neurotrophin neuroprotection slow release gene therapy cell transplantation |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
